Ivabradina Viatris

Ivabradine, the active ingredient in Ivabradina Viatris, is a If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients. GNH USA supplies Ivabradina Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Viatris acts on the cardiac If current to lower heart rate, benefiting conditions where heart‑rate reduction improves outcomes. - Chronic stable angina: decreases the frequency of angina attacks by reducing myocardial oxygen demand through heart‑rate lowering. - Heart failure with reduced ejection fraction: improves symptoms and may lower hospitalization risk by maintaining a more favorable heart‑rate profile.

Ivabradina Viatris may cause a range of adverse reactions. Most are mild and reversible, but clinicians should remain vigilant for serious events.

Common Side Effects: - Visual disturbances (phosphenes) - Headache - Dizziness - Fatigue - Nausea - Blurred vision

Serious or Rare Side Effects: - Severe bradycardia - Atrial fibrillation - Symptomatic hypotension - Visual loss - Allergic reactions (rash, angioedema) - Hepatic dysfunction

Before initiating therapy, consider the following safety measures. - Heart‑rate monitoring: verify resting heart rate is ≥70 bpm before starting. - Severe hypotension: avoid use in patients with systolic blood pressure <90 mmHg. - Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Sick‑sinus syndrome or atrioventricular block: contraindicated unless a pacemaker is present. - Acute decompensated heart failure: do not initiate during this phase. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradina Viatris can interact with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine exposure. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem): risk of excessive heart‑rate reduction. - Amiodarone: additive effect on cardiac conduction.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.